Jim Cramer Breaks Down Johnson & Johnson's Strong Performance and Outlook

Johnson & Johnson's Impressive Quarter

• 💡 Johnson & Johnson (J&J) demonstrated a strong quarter, with oncology sales showing incredible growth at 24%.
• 🧠 The company has a new treatment for bladder cancer, described as great maintenance therapy.
• 📈 Medtech performance was sensational, defying expectations that it might be weaker.
• 💊 Neuroscience also saw significant growth at 15%, driven by the anti-depression drug Bravado.

Outlook and Market Bellwether

• 🎯 When J&J raises its outlook, it tends to stick, making it a stock to watch.
• 📊 The company's performance could serve as a bellwether for the broader healthcare group.

Tariffs and US Manufacturing

• ⚠️ While tariffs are a concern, J&J is less impacted because it manufactures most of its products in the United States.
• 🇺🇸 This contrasts with companies like Novo Nordisk, which would face tariffs, making the situation very positive for US-based manufacturing and companies like J&J.